Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid tumours. - Chronic myeloid leukemia (CML): suppresses leukemic cell proliferation and induces cytogenetic remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT or PDGFR mutations.

Adverse reactions may vary in frequency and severity. Patients should be monitored regularly for both common and serious events.

Common Side Effects: - Nausea - Edema (peripheral swelling) - Muscle cramps or pain - Fatigue - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Life‑threatening bleeding events

Before initiating therapy, clinicians should assess baseline organ function and monitor patients throughout treatment. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function monitoring: check transaminases and bilirubin at baseline and periodically. - Cardiac assessment: evaluate cardiac history and monitor for signs of heart failure. - Hypersensitivity: discontinue if severe allergic reactions occur. - Renal impairment: adjust dosing in patients with significant renal dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with drugs that affect its metabolism or increase the risk of toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: increased serum digoxin levels have been reported. - QT‑prolonging agents (e.g., quinidine, sotalol): may increase risk of arrhythmia. - Vaccines: live attenuated vaccines should be avoided during treatment.